Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Abbvie Inc. Drug Patent Portfolio

Abbvie Inc. owns 1 purple book drug protected by 66 US patents Given below is the list of Abbvie Inc.'s drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9550826 Glycoengineered binding protein compositions 14 Nov, 2034
Active
US9499614 Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides 14 Mar, 2034
Active
US9150645 Cell culture methods to reduce acidic species 13 May, 2033
Active
US9266949 Low acidic species compositions and methods for producing and using the same 13 May, 2033
Active
US9315574 Low acidic species compositions and methods for producing and using the same 21 Apr, 2033
Active
US9085618 Low acidic species compositions and methods for producing and using the same 14 Mar, 2033
Active
US9181337 Modulated lysine variant species compositions and methods for producing and using the same 14 Mar, 2033
Active
US9181572 Methods to modulate lysine variant distribution 14 Mar, 2033
Active
US9290568 Methods to control protein heterogeneity 14 Mar, 2033
Active
US9334319 Low acidic species compositions 14 Mar, 2033
Active
US9346879 Protein purification methods to reduce acidic species 14 Mar, 2033
Active
US9359434 Cell culture methods to reduce acidic species 14 Mar, 2033
Active
US9499616 Modulated lysine variant species compositions and methods for producing and using the same 14 Mar, 2033
Active
US9708400 Methods to modulate lysine variant distribution 14 Mar, 2033
Active
US9062106 Methods for controlling the galactosylation profile of recombinantly-expressed proteins 26 Apr, 2032
Active
US9090688 Methods for controlling the galactosylation profile of recombinantly-expressed proteins 26 Apr, 2032
Active
US9505834 Methods for controlling the galactosylation profile of recombinantly-expressed proteins 26 Apr, 2032
Active
US9522953 Low acidic species compositions and methods for producing and using the same 26 Apr, 2032
Active
US9683033 Cell culture methods to reduce acidic species 26 Apr, 2032
Active
US9957318 Protein purification methods to reduce acidic species 26 Apr, 2032
Active
US8708968 Removal of needle shields from syringes and automatic injection devices 24 Jan, 2032
Active
US9339610 Removal of needle shield from syringes and automatic injection devices 24 Jan, 2032
Active
US9624295 Uses and compositions for treatment of psoriatic arthritis 31 Mar, 2031
Active
US8999337 Methods for treating juvenile idiopathic arthritis by inhibition of TNFα 06 Feb, 2031
Active
US8420081 Antibody formulations and methods of making same 13 Jan, 2030
Active
US11167030 Protein formulations and methods of making same 28 Nov, 2028
Active
US11191834 Protein formulations and methods of making same 28 Nov, 2028
Active
US9085619 Anti-TNF antibody formulations 28 Nov, 2028
Active
US9284370 Methods for treating juvenile idiopathic arthritis 10 Jun, 2028
Active
US9669093 Methods for treating juvenile idiopathic arthritis 10 Jun, 2028
Active
US8889136 Multiple-variable dose regimen for treating TNFα-related disorders 09 Oct, 2027
Active
US8663945 Methods of producing anti-TNF-alpha antibodies in mammalian cell culture 13 Sep, 2027
Active
US8906646 Fed-batch method of making human anti-TNF-alpha antibody 13 Sep, 2027
Active
US8911964 Fed-batch method of making human anti-TNF-alpha antibody 13 Sep, 2027
Active
US9090867 Fed-batch method of making anti-TNF-alpha antibody 13 Sep, 2027
Active
US9234032 Fed-batch methods for producing adalimumab 13 Sep, 2027
Active
US9284371 Methods of producing adalimumab 13 Sep, 2027
Active
US8715664 Use of human TNFα antibodies for treatment of erosive polyarthritis 24 Jul, 2027
Active
US8926975 Method of treating ankylosing spondylitis 08 Jun, 2027
Active
US11083792 Purified antibody composition 04 Apr, 2027
Active
US8231876 Purified antibody composition 04 Apr, 2027
Active
US8883156 Purified antibody composition 04 Apr, 2027
Active
US8895009 Purified antibody composition 04 Apr, 2027
Active
US8906372 Purified antibody composition 04 Apr, 2027
Active
US8916153 Purified antibody composition 04 Apr, 2027
Active
US9096666 Purified antibody composition 04 Apr, 2027
Active
US9102723 Purified antibody composition 04 Apr, 2027
Active
US9273132 Purified antibody composition 04 Apr, 2027
Active
US9328165 Purified antibody composition 04 Apr, 2027
Active
US9913902 Purified antibody composition 04 Apr, 2027
Active
US8808700 Use of TNF alpha inhibitor for treatment of erosive polyarthritis 16 May, 2026
Active
US8961973 Multiple-variable dose regimen for treating TNFα-related disorders 11 Apr, 2025
Active
US8961974 Multiple-variable dose regimen for treating TNFα-related disorders 11 Apr, 2025
Active
US8986693 Use of TNFα inhibitor for treatment of psoriasis 11 Apr, 2025
Active
US9061005 Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease 11 Apr, 2025
Active
US9187559 Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease 11 Apr, 2025
Active
US9512216 Use of TNFα inhibitor 11 Apr, 2025
Active
US8906373 Use of TNF-alpha inhibitor for treatment of psoriasis 18 Jul, 2023
Active
US9067992 Use of TNFα inhibitor for treatment of psoriatic arthritis 18 Jul, 2023
Active
US9085620 Use of TNFα inhibitor for treatment of psoriatic arthritis 18 Jul, 2023
Active
US9090689 Use of TNFα inhibitor for treatment of psoriasis 18 Jul, 2023
Active
US6805686 Autoinjector with extendable needle protector shroud 06 May, 2023
Active
US8911737 Methods of administering anti-TNFα antibodies 05 Jun, 2022
Active
US8974790 Methods of administering anti-TNFα antibodies 05 Jun, 2022
Active
US8992926 Methods of administering anti-TNFα antibodies 05 Jun, 2022
Active
US9546212 Methods of administering anti-TNFα antibodies 05 Jun, 2022
Active


Abbvie Inc.'s Family Patents


Family Patents



Abbvie Inc. Drug List

Given below is the complete list of Abbvie Inc.'s drugs and the patents protecting them.


1. Humira

Humira is protected by 66 patents, out of which 9 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9550826 Glycoengineered binding protein compositions 14 Nov, 2034
(10 years from now)
Active
US9499614 Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides 14 Mar, 2034
(9 years from now)
Active
US9150645 Cell culture methods to reduce acidic species 13 May, 2033
(8 years from now)
Active
US9266949 Low acidic species compositions and methods for producing and using the same 13 May, 2033
(8 years from now)
Active
US9315574 Low acidic species compositions and methods for producing and using the same 21 Apr, 2033
(8 years from now)
Active
US9085618 Low acidic species compositions and methods for producing and using the same 14 Mar, 2033
(8 years from now)
Active
US9181337 Modulated lysine variant species compositions and methods for producing and using the same 14 Mar, 2033
(8 years from now)
Active
US9181572 Methods to modulate lysine variant distribution 14 Mar, 2033
(8 years from now)
Active
US9290568 Methods to control protein heterogeneity 14 Mar, 2033
(8 years from now)
Active
US9334319 Low acidic species compositions 14 Mar, 2033
(8 years from now)
Active
US9346879 Protein purification methods to reduce acidic species 14 Mar, 2033
(8 years from now)
Active
US9359434 Cell culture methods to reduce acidic species 14 Mar, 2033
(8 years from now)
Active
US9499616 Modulated lysine variant species compositions and methods for producing and using the same 14 Mar, 2033
(8 years from now)
Active
US9708400 Methods to modulate lysine variant distribution 14 Mar, 2033
(8 years from now)
Active
US9062106 Methods for controlling the galactosylation profile of recombinantly-expressed proteins 26 Apr, 2032
(7 years from now)
Active
US9090688 Methods for controlling the galactosylation profile of recombinantly-expressed proteins 26 Apr, 2032
(7 years from now)
Active
US9505834 Methods for controlling the galactosylation profile of recombinantly-expressed proteins 26 Apr, 2032
(7 years from now)
Active
US9522953 Low acidic species compositions and methods for producing and using the same 26 Apr, 2032
(7 years from now)
Active
US9683033 Cell culture methods to reduce acidic species 26 Apr, 2032
(7 years from now)
Active
US9957318 Protein purification methods to reduce acidic species 26 Apr, 2032
(7 years from now)
Active
US8708968 Removal of needle shields from syringes and automatic injection devices 24 Jan, 2032
(7 years from now)
Active
US9339610 Removal of needle shield from syringes and automatic injection devices 24 Jan, 2032
(7 years from now)
Active
US9624295 Uses and compositions for treatment of psoriatic arthritis 31 Mar, 2031
(6 years from now)
Active
US8999337 Methods for treating juvenile idiopathic arthritis by inhibition of TNFα 06 Feb, 2031
(6 years from now)
Active
US8420081 Antibody formulations and methods of making same 13 Jan, 2030
(5 years from now)
Active
US11167030 Protein formulations and methods of making same 28 Nov, 2028
(4 years from now)
Active
US11191834 Protein formulations and methods of making same 28 Nov, 2028
(4 years from now)
Active
US9085619 Anti-TNF antibody formulations 28 Nov, 2028
(4 years from now)
Active
US9284370 Methods for treating juvenile idiopathic arthritis 10 Jun, 2028
(3 years from now)
Active
US9669093 Methods for treating juvenile idiopathic arthritis 10 Jun, 2028
(3 years from now)
Active
US8889136 Multiple-variable dose regimen for treating TNFα-related disorders 09 Oct, 2027
(2 years from now)
Active
US8663945 Methods of producing anti-TNF-alpha antibodies in mammalian cell culture 13 Sep, 2027
(2 years from now)
Active
US8906646 Fed-batch method of making human anti-TNF-alpha antibody 13 Sep, 2027
(2 years from now)
Active
US8911964 Fed-batch method of making human anti-TNF-alpha antibody 13 Sep, 2027
(2 years from now)
Active
US9090867 Fed-batch method of making anti-TNF-alpha antibody 13 Sep, 2027
(2 years from now)
Active
US9234032 Fed-batch methods for producing adalimumab 13 Sep, 2027
(2 years from now)
Active
US9284371 Methods of producing adalimumab 13 Sep, 2027
(2 years from now)
Active
US8715664 Use of human TNFα antibodies for treatment of erosive polyarthritis 24 Jul, 2027
(2 years from now)
Active
US8926975 Method of treating ankylosing spondylitis 08 Jun, 2027
(2 years from now)
Active
US11083792 Purified antibody composition 04 Apr, 2027
(2 years from now)
Active
US8231876 Purified antibody composition 04 Apr, 2027
(2 years from now)
Active
US8883156 Purified antibody composition 04 Apr, 2027
(2 years from now)
Active
US8895009 Purified antibody composition 04 Apr, 2027
(2 years from now)
Active
US8906372 Purified antibody composition 04 Apr, 2027
(2 years from now)
Active
US8916153 Purified antibody composition 04 Apr, 2027
(2 years from now)
Active
US9096666 Purified antibody composition 04 Apr, 2027
(2 years from now)
Active
US9102723 Purified antibody composition 04 Apr, 2027
(2 years from now)
Active
US9273132 Purified antibody composition 04 Apr, 2027
(2 years from now)
Active
US9328165 Purified antibody composition 04 Apr, 2027
(2 years from now)
Active
US9913902 Purified antibody composition 04 Apr, 2027
(2 years from now)
Active
US8808700 Use of TNF alpha inhibitor for treatment of erosive polyarthritis 16 May, 2026
(1 year, 5 months from now)
Active
US8961973 Multiple-variable dose regimen for treating TNFα-related disorders 11 Apr, 2025
(4 months from now)
Active
US8961974 Multiple-variable dose regimen for treating TNFα-related disorders 11 Apr, 2025
(4 months from now)
Active
US8986693 Use of TNFα inhibitor for treatment of psoriasis 11 Apr, 2025
(4 months from now)
Active
US9061005 Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease 11 Apr, 2025
(4 months from now)
Active
US9187559 Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease 11 Apr, 2025
(4 months from now)
Active
US9512216 Use of TNFα inhibitor 11 Apr, 2025
(4 months from now)
Active
US8906373 Use of TNF-alpha inhibitor for treatment of psoriasis 18 Jul, 2023
(1 year, 3 months ago)
Expired
US9067992 Use of TNFα inhibitor for treatment of psoriatic arthritis 18 Jul, 2023
(1 year, 3 months ago)
Expired
US9085620 Use of TNFα inhibitor for treatment of psoriatic arthritis 18 Jul, 2023
(1 year, 3 months ago)
Expired
US9090689 Use of TNFα inhibitor for treatment of psoriasis 18 Jul, 2023
(1 year, 3 months ago)
Expired
US6805686 Autoinjector with extendable needle protector shroud 06 May, 2023
(1 year, 6 months ago)
Expired
US8911737 Methods of administering anti-TNFα antibodies 05 Jun, 2022
(2 years ago)
Expired
US8974790 Methods of administering anti-TNFα antibodies 05 Jun, 2022
(2 years ago)
Expired
US8992926 Methods of administering anti-TNFα antibodies 05 Jun, 2022
(2 years ago)
Expired
US9546212 Methods of administering anti-TNFα antibodies 05 Jun, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humira's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List